Promacta patent expiration?

When Does Promacta Patent Expiration Occur?

Promacta, also known as eltrombopag, is an oral thrombopoietin receptor agonist used for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenia (cITP) and aplastic anemia (AA).

According to PatentWatch, the eltrombopag patent, held by GlaxoSmithKline (GSK), was granted in 2004 and has been subject to multiple patent extensions and exclusivity provisions [1].

What is Promacta Used For?

Promacta is used for treating patients with chronic immune thrombocytopenia (cITP) who have failed previous treatments. It works by stimulating the bone marrow to produce more platelets, thus helping to improve platelet counts in patients with low counts.

Who Makes Promacta?

Promacta is manufactured and marketed by GlaxoSmithKline (GSK), a multinational pharmaceutical company with a presence in over 150 countries.

Is Promacta Available as a Generic?

As of now, Promacta remains a branded medication. When the patent expires, biosimilar versions of eltrombopag could become available. According to DrugPatentWatch.com, the eltrombopag patent is scheduled to expire in 2027 [2].

How Long Will Promacta's Patent Exclusivity Last?

The patent exclusivity for Promacta is set to expire in 2027, at which point, biosimilars can enter the market. However, regulatory approval and market entry times may vary depending on various factors, including the approval processes in different countries and potential patent litigation.

What Happens When Promacta's Patent Expiration Takes Place?

Upon patent expiration, generic companies can begin marketing their versions of eltrombopag, potentially increasing competition and reducing medication costs.

Sources:

[1] PatentWatch: Eltrombopag Patent Details. Retrieved June 22, 2023, from https://patentwatch.com/patent/US20040265351

[2] DrugPatentWatch.com: Eltrombopag Patent Expiration. Retrieved June 22, 2023, from https://www.drugpatentwatch.com/drugs/eltrombopag